telaprevir experience from turkey

Telaprevir Experience From Turkey

BACKGROUND In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1. OBJECTIVES In Turkey, telaprevir has been used since March 2013. We aimed to evaluate res...

Comment to “Telaprevir Experience From Turkey”

We have read with great interest the article entitled " Telaprevir experience from Turkey " by Komur et al. recently (1). First of all, we have applauded the efforts of the authors and the editors of journal for putting forward this controversial and wondered topic for us. Currently, the hepatitis C treatment is in a very dynamic situation, due to newly introduced potent drugs. Therefore, the m...

comment to “telaprevir experience from turkey”

Tuberculosis verrucosa cutis. Experience from eastern Turkey.

T verrucosa cutis (TBVC) is a paucibacillary form of cutaneous tuberculosis caused by exogenous reinfection in previously sensitized individuals. Inoculation occurs at sites of minor wounds or abrasions, and rarely from the patient’s own sputum. The TBVC usually occurs on the hands in adults, and on the lower extremities in children. In western countries, TBVC is a rare form of cutaneous tuberc...

Telaprevir

Telaprevir (LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. It is being developed by Vertex Pharmaceuticals and its licensees for the treatment of HCV infections and has recently been submitted to the US FDA for approval. As the first ever HCV protease inhibitor in phase III develo...

Gnathic osteosarcomas, experience of four institutions from Turkey.

Osteosarcoma is the most frequent primary gnathic sarcoma. Neither the etiology nor the variables effecting the prognosis are fully known due mostly to the rarity of gnathic osteosarcomas. To date a considerable number of clinicopathologic features have been suggested in the evaluation of gnathic osteosarcomas. Still there is a need to experience on several aspects of management. The aim of thi...